Loading…
Pharmaceuticals and Biotechnology · NSE · period ending 2026-03-31
Loading chart…
✓ Core business is permissible and non-compliant income is 0.52% of revenue (limit 5%).
| Ratio | Value | Limit | Result |
|---|---|---|---|
| Interest-bearing debt / market cap | 5.94% | < 30% | Pass |
| Interest-bearing investments / market cap | 0.61% | < 30% | Pass |
The underlying figures and the filing citations they came from are available with a free account.
Sign up free0.52% of any dividend from WOCKPHARMA should be given to charity. Calculate your amount →
WOCKPHARMA exhibits very strong gains across all recent horizons, with price close to its 52-week high and the 50-day average above the 200-day despite high volatility. This reflects a powerful ongoing uptrend without a specific sector sentiment cue here.
Computed from delayed price history and desk sentiment. Educational context only — not investment advice or a price prediction.
Compliance watch: verdict re-verified against live market cap on 13 Jun 2026 · rechecked every 6 hours · filings reviewed quarterly.